Market Failure? Lower Drug Prices Don't Improve Access In Rheumatoid Arthritis
Executive Summary
'Perverse incentives' guide US pricing for rheumatoid arthritis drugs, stakeholders say at policy roundtable convened by Institute for Clinical and Economic Review.
You may also be interested in...
Sanofi/Regeneron's Kevzara Priced To Break Into A Crowded Market
The partners are looking to create a compelling value proposition for the interleukin-6 inhibitor, approved by FDA to treat moderate to severe RA, by pricing it below the market-leading anti-TNFs.
Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA
FDA complete response letter seeks additional data on dosing and other safety concerns, delaying potential approval for an NDA that already had been pushed back three months. Interleukin-6 inhibitors sarilumab and sirukumab, now under review at FDA, both could obtain approval before baricitinib.
Sanofi, Regeneron Setting 'New Paradigm' With Dupixent Pricing In US?
Companies employed collaborative outreach with payers to arrive at 'responsible' price for atopic dermatitis biologic.